Loading clinical trials...
Loading clinical trials...
A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.
Age
6 - 17 years
Sex
ALL
Healthy Volunteers
No
Omaha, Nebraska, United States
Livingston, New Jersey, United States
New Hyde Park, New York, United States
Valhalla, New York, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Duncansville, Pennsylvania, United States
Dallas, Texas, United States
Seattle, Washington, United States
Milwaukee, Wisconsin, United States
Start Date
December 1, 2003
Primary Completion Date
June 1, 2006
Completion Date
November 1, 2011
Last Updated
January 18, 2017
214
ACTUAL participants
Abatacept
DRUG
Placebo
DRUG
Abatacept
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT05545839
NCT05114343
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions